Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1981 Jul 1;59(13):737-42.
doi: 10.1007/BF01721261.

[Stage IIIB and IVB Hodgkin's disease. Response to chemotherapy, relapses, survival rates (author's transl)]

[Article in German]

[Stage IIIB and IVB Hodgkin's disease. Response to chemotherapy, relapses, survival rates (author's transl)]

[Article in German]
R Kuse et al. Klin Wochenschr. .

Abstract

Thirty-two of 71 (45%) stage IIIB and IVB patients up to the age of 60 achieved a complete remission (CR) by initial COPP-chemotherapy. Twelve additional cases were free of symptoms after COPP, but showed persistent disease at postprimary laparotomy or within 3 months after cessation of chemotherapy. Forty-four per cent (n = 17) of this initial COPP failures could also be brought to CR by ABVD-chemotherapy or/and radiotherapy within 7 to 51 months. Cases with lymphocytic depletion reached CR in only 31% (N = 5/16) in comparison to 80% (n = 44/55) of the three other histological subtypes. Without additional consolidation therapy 60% relapsed, but only 11% after adjuvant total-nodal irradiation. An increase of side effects after therapy has not been observed so far. Patients with once attained CR have a survival probability of 93% after nearly 8 years from diagnosis. For the whole stage IIIB/IVB group the values were 85% up to the age of 30 (n = 28) and 60% for the age group of 31-60 (N = 43). They were clearly higher than in the 1966-1971 patients who showed values o 39% nd 41%, respectively. Beyond the stage of 60 (n = 15) the survival probability of 10% after 3 years in comparison to former 15% revealed no improvement.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer. 1976 Aug;38(2):667-71 - PubMed
    1. Cancer. 1976 Jun;37(6):2826-33 - PubMed
    1. Ann Intern Med. 1970 Dec;73(6):881-95 - PubMed
    1. Nouv Rev Fr Hematol Blood Cells. 1977;18(2):473-83 - PubMed
    1. Schweiz Med Wochenschr. 1976 Apr 10;106(15):507-13 - PubMed

Publication types

MeSH terms

LinkOut - more resources